4/30/2023 0 Comments Download mendeley 32 bitDorothy McCabe is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. Stevenson reports participating on an advisory board for Boehringer Ingelheim. Slightly more than 50% of respondents felt that they were moderately or very comfortable in responding to patients’ biosimilar questions.ĭisclosures: James G. Only 11% of respondents knew that no biosimilars were designated as interchangeable at the time of the survey, with a numerically greater proportion of managed care pharmacists showing awareness than other groups. However, 53% responded that they felt it was appropriate for a pharmacist to dispense an interchangeable in place of its reference product without authorization from the prescriber if consistent with state law a numerically smaller proportion of community pharmacists understood this concept than the other groups (50% vs. Only 20% understood that a pharmacist can substitute a Food and Drug Administration–approved interchangeable without approval of the prescriber. Overall, 87% and 91% of respondents knew that the biosimilar had equivalent efficacy and safety, respectively, to its reference product. These respondents worked in a community setting (66%), outpatient or ambulatory or other setting (16%), hospital or health system setting (14%), or managed care (5%). Data are reported for 507 of 992 respondents (265 did not meet eligibility criteria, 220 responded after the survey closed), including 498 pharmacists and 9 CPTs.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |